C3 and paroxysmal nocturnal hemoglobinuria: Here, we show that the newly FDA- and EMA-approved C3 inhibitor pegcetacoplan is able to control hemolysis in the majority of complement inhibitor-naïve patients and improve hematologic parameters, thus demonstrating that it is a viable treatment option for treatment-naïve patients with PNH.